Skip to content

For Patients
For Providers

For Patients
For Providers
Join The Waitlist

Join The Waitlist

Journey Resource Center

News

Our Journey Continues: Opening Access to Millions with Diabetes

January 18, 2024

Journey Biosciences Named Rising Star Finalist for Digital Health Awards

News

Journey Biosciences Named Finalist in Digital Health Hub Foundation’s Annual Awards

September 26, 2023

Digital Health Awards: Journey Biosciences Quarterfinalist Badge

News

Journey Biosciences Named a 'Rising Star' Quarterfinalist in Prestigious Digital Health Awards

September 5, 2023

News

Journey Biosciences Selected for StartUp Health’s T1D Moonshot

March 23, 2023

News

AMA Grants Journey Biosciences CPT® PLA Code for NaviDKD®

January 9, 2023

News

Journey Biosciences launches NaviDKD® to predict diabetes-related kidney complications

December 1, 2022

News

This New Product Could Help Identify Your Risk of Developing Kidney Disease

September 16, 2022

News

New Study Validates Predictive Biomarkers in Diabetic Kidney Disease

May 3, 2022

News

Journey Biosciences appoints Greg Dooley & Gordie Nye to its board of directors

October 28, 2021

News

Journey Biosciences and Cardinal Health OptiFreight® Logistics Collaborate to Improve Long-Term Diabetes Care

October 14, 2021

News

Introducing Journey Biosciences and NaviDKD: Preventing Diabetes-Related Kidney Complications

September 30, 2021

support@journeybio.life
(877) 618-1005

The Science Behind NaviDKD

Contact Us
Resource Center
Privacy Policy
Terms and Conditions

NaviDKD is a Lab Developed Test (LDT) developed and its performance characteristics were determined by Journey Biosciences. NaviDKD is performed in a CLIA certified laboratory and is intended for clinical purposes. NaviDKD has not been cleared by the US Food and Drug Administration. NaviDKD has been clinically validated and indicated for use as an aid to predict patients at risk for developing Diabetes-Related Kidney Disease (DKD) at a time in its development when appropriate preventative treatments can be initiated. NaviDKD is indicated for use in individuals 18 years of age or older diagnosed with Type 1, Type 2 or LADA diabetes.